Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for clues to drug resistance in head and neck cancer

NCT ID NCT07471009

Knowledge-focused Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will collect tumor and blood samples from 120 people with head and neck squamous cell carcinoma. Researchers will create mouse models from the samples and analyze molecular markers to understand resistance to standard therapies. The goal is to find new treatment targets for patients whose cancer stops responding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could identify new drug targets for patients whose head and neck cancer has become resistant to standard therapy.
What could go wrong
This is an observational study, not a treatment trial. It is early-stage research that may not lead directly to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Oct 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The SPAR study will involve approximately 120 patients with head and neck squamous cell carcinoma (HNSCC). The retrospective phase will analyze tissue samples (FFPE) from about 40 patients treated with cetuximab over the last 10 years at the IRCCS in Bologna, regardless of their disease stage. The prospective phase will enroll 80 surgical candidates over the next 5 years, collecting samples during standard clinical care to develop PDX models and perform molecular analysis. For both groups, clinical, demographic, and outcome data will be collected following the acquisition of informed consent.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients aged 18 years or older at the time of tissue collection 2. Obtaining written informed consent For patients enrolled retrospectively: 1\. Patients with squamous cell carcinoma of the head and neck treated by the Medical Oncology Unit because they underwent medical treatment with cetuximab in the last 10 years following histological diagnosis carried out in the Otolaryngology or Maxillofacial Surgery Units For prospectively enrolled patients: 1\. Patients with squamous cell carcinoma of the head and neck who will be recruited over the next 5 years Exclusion Criteria: * For patients enrolled retrospectively: Patients with material that is qualitatively and/or quantitatively unsuitable for the necessary immunohistochemical and molecular investigations. \- For patients enrolled prospectively: None, except for diagnoses other than squamous cell carcinoma.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Squamous cell tumors of the head and neck (HNSCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma neoplasm Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Squamous cell tumors of the head and neck (HNSCC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IRCSS Azienda Ospedaliero-Universitaria di Bologna

    Bologna, Bologna, 40138, Italy